

16. The lyophilizate of claim 13, further comprising a buffering agent or an isotoning agent.

17. The lyophilizate of claim 13, wherein the lyophilizate is storage-stable for a time period of at least three months at a temperature of about 4-12°C.

18. The lyophilizate of claim 13, wherein the lyophilizate is storage-stable for a time period of at least three months at a temperature of about 18-23°C.

19. The lyophilizate of claim 13, wherein the sugar comprises at least one member selected from the group consisting of a monosaccharide, a disaccharide and a trisaccharide.

20. The lyophilizate of claim 13, wherein the sugar comprises at least one member selected from the group consisting of glucose, mannose, galactose, fructose, sorbose, sucrose, lactose, maltose, cellobiose, gentiobiose, isomaltose, trehalose and raffinose.

21. The lyophilizate of claim 20, wherein the sugar comprises at least one member selected from the group consisting of sucrose, lactose, maltose, cellobiose, gentiobiose, isomaltose, trehalose and raffinose.

22. The lyophilizate of claim 13, wherein the amino sugar comprises at least one member selected from the group consisting of glucosamine, N-methyl-glucosamine, galactosamine and neuraminic acid.

23. The lyophilizate of claim 13, wherein the amino acid comprises at least one member selected from the group consisting of arginine, lysine, histidine, ornithine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine and tryptophan.

24. The lyophilizate of claim 13, wherein the surfactant comprises a polysorbate or a polyoxyethylene-polyoxypropylene polymer.

25. The lyophilizate of claim 13, wherein the monoclonal antibody or the polyclonal antibody has a molecular weight of 50-200 kDa per monomer unit.

26. The lyophilizate of claim 13, wherein the monoclonal antibody or the polyclonal antibody is directed against an antigen selected from the group consisting of hepatitis B virus, AIDS virus, cytomegalovirus, meningoencephalitis virus, rubella virus, measles virus, rabies pathogen, *Pseudomonas aeruginosa*, varicella-zoster virus, tetanus pathogen, van Willebrandt factor, nerve growth factor receptor, platelet derived growth factor receptor, selectin, integrin and diphtheria pathogen.

27. A lyophilizate, consisting essentially of
- (1) a monoclonal antibody or a polyclonal antibody;
 - (2) a sugar or an amino sugar;
 - (3) at least one amino acid;
 - (4) a surfactant; and
 - (5) an inorganic acid as a buffering agent.

28. A liquid pharmaceutical composition comprising the lyophilizate of claim 13 dissolved in a physiologically acceptable solution.

29. The liquid pharmaceutical composition of claim 28, wherein the composition has a pH value of 5-8.

30. The liquid pharmaceutical composition of claim 28, wherein the composition contains 1-10 mg/ml of antibody.

31. The liquid pharmaceutical composition of claim 28, wherein the composition contains up to 200 mg/ml of sugar or amino sugar.